Evidence map›Paper›PMID 31104839›Full record

ArticleCell2019

SCAF4 and SCAF8, mRNA Anti-Terminator Proteins.

Lea H Gregersen, Richard Mitter, Alejandro P Ugalde, Takayuki Nojima, Nicholas J Proudfoot, Reuven Agami, Aengus Stewart, Jesper Q Svejstrup

Open access · hybridAbstract read
In one paragraph

Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 1 synthesis or guideline pooled it, 153 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. PTAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Lea H GregersenMechanisms of Transcription Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Richard MitterBioinformatics and Biostatistics, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Alejandro P UgaldeThe Netherlands Cancer Institute (NKI-AVL), Plesmanlaan 121, 1066 CX Amsterdam, Netherlands.
Takayuki NojimaSir William Dunn School of Pathology, University of Oxford, South Parks Road, OX1 3RE Oxford, UK.
Nicholas J ProudfootSir William Dunn School of Pathology, University of Oxford, South Parks Road, OX1 3RE Oxford, UK.
Reuven AgamiThe Netherlands Cancer Institute (NKI-AVL), Plesmanlaan 121, 1066 CX Amsterdam, Netherlands.
Aengus StewartBioinformatics and Biostatistics, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Jesper Q SvejstrupMechanisms of Transcription Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address: jesper.svejstrup@crick.ac.uk.
The Francis Crick Institute · GBThe Netherlands Cancer Institute · NLUniversity of Oxford · GB

Funding

Cancer Research UK 11567Cancer Research UK FC001166Wellcome Trust FC001166
6 · The paper itself

Abstract

Accurate regulation of mRNA termination is required for correct gene expression. Here, we describe a role for SCAF4 and SCAF8 as anti-terminators, suppressing the use of early, alternative polyadenylation (polyA) sites. The SCAF4/8 proteins bind the hyper-phosphorylated RNAPII C-terminal repeat domain (CTD) phosphorylated on both Ser2 and Ser5 and are detected at early, alternative polyA sites. Concomitant knockout of human SCAF4 and SCAF8 results in altered polyA selection and subsequent early termination, leading to expression of truncated mRNAs and proteins lacking functional domains and is cell lethal. While SCAF4 and SCAF8 work redundantly to suppress early mRNA termination, they also have independent, non-essential functions. SCAF8 is an RNAPII elongation factor, whereas SCAF4 is required for correct termination at canonical, distal transcription termination sites in the presence of SCAF8. Together, SCAF4 and SCAF8 coordinate the transition between elongation and termination, ensuring correct polyA site selection and RNAPII transcriptional termination in human cells.

Indexed as

Transcription Elongation, GeneticTranscription Termination, GeneticHEK293 CellsHumansPoly AProtein DomainsRNA-Binding ProteinsRNA, MessengerRNA Polymerase IISerine-Arginine Splicing FactorsPoly ARNA-Binding ProteinsRNA, MessengerRNA Polymerase IISCAF4 protein, humanSCAF8 protein, humanSerine-Arginine Splicing Factorsanti-terminationco-transcriptional mRNA processingCTD phosphorylationC-terminal repeat domain (CTD)polyadenylationRNA polymerase IISCAF4SCAF8transcript elongationtranscriptional termination

Identifiers

PMID31104839
PMCPMC6579486
OpenAlexW2944834243

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.